Archelos J J, Jung S, Mäurer M, Schmied M, Lassmann H, Tamatani T, Miyasaka M, Toyka K V, Hartung H P
Department of Neurology, Julius-Maximilians-Universität, Würzburg, Germany.
Ann Neurol. 1993 Aug;34(2):145-54. doi: 10.1002/ana.410340209.
Experimental autoimmune encephalomyelitis (EAE) was induced in Lewis rats by active immunization with myelin from guinea pig spinal cord by the encephalitogenic myelin basic protein or by adoptive transfer using myelin basic protein-specific CD4-positive T cells. Treatment with purified monoclonal antibody (1A-29) to the intercellular adhesion molecule-1 and its F(ab')2 fragments efficiently suppressed active EAE. Control treatment with an irrelevant antibody or saline did not alter the course of the disease. Histological sections of the central nervous system showed a pronounced reduction of inflammatory infiltrates during treatment with antibody to intercellular adhesion molecule-1. In the adoptive transfer model of EAE, 1A-29 had only a minor effect. Proliferation assays on lymph node cells ex vivo from 1A-29- and saline-treated animals were performed. Administration of 1A-29 suppressed antigen-specific T-cell proliferation. The differential effects in EAE versus adoptive transfer EAE suggest that 1A-29 acts predominantly on the induction phase of the immune response and, to a lesser extent, on the transendothelial migration of T cells. We conclude that intercellular adhesion molecule-1-dependent pathways are critically involved in the pathogenesis of EAE and that antibodies to leukocyte adhesion molecules could be a novel therapeutic approach to autoimmune disease of the central nervous system.
通过用豚鼠脊髓髓磷脂、致脑炎性髓鞘碱性蛋白进行主动免疫,或使用髓鞘碱性蛋白特异性CD4阳性T细胞进行过继转移,在Lewis大鼠中诱导实验性自身免疫性脑脊髓炎(EAE)。用针对细胞间黏附分子-1的纯化单克隆抗体(1A-29)及其F(ab')2片段进行治疗可有效抑制活动性EAE。用无关抗体或生理盐水进行对照治疗未改变疾病进程。中枢神经系统的组织学切片显示,在用细胞间黏附分子-1抗体治疗期间,炎性浸润明显减少。在EAE的过继转移模型中,1A-29只有轻微作用。对来自1A-29和生理盐水处理动物的体外淋巴结细胞进行增殖测定。给予1A-29可抑制抗原特异性T细胞增殖。EAE与过继转移EAE中的不同作用表明,1A-29主要作用于免疫反应的诱导阶段,在较小程度上作用于T细胞的跨内皮迁移。我们得出结论,细胞间黏附分子-1依赖性途径在EAE的发病机制中起关键作用,并且针对白细胞黏附分子的抗体可能是治疗中枢神经系统自身免疫性疾病的一种新方法。